Health
Retatrutide: The Triple Agonist Still Proving Itself
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026
Loading
Search
Results
7 stories for“triple agonist”
Health
Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026
Health
Retatrutide's Third Receptor Is the Hormone That Raises Blood Sugar. Adding It On Purpose Is the Whole Idea
Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
Health
What GLP-1 Drugs Actually Do Inside Your Body
GLP-1 receptor agonists did not start as weight loss drugs. Here is the biology behind Ozempic, Mounjaro and the hormone they mimic.
Jan 25, 2024
Health
Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024
Health
Ozempic in a Tablet: What the Rebrand of Oral Semaglutide Actually Changes
Novo Nordisk folded Rybelsus into the Ozempic name in May and put a self-pay price on it. Getting a peptide to survive the stomach is a real achievement, but the tablet is not simply the injection in another form.
Aug 11, 2026
Health
Retatrutide Is Not Approved in Any Country. It Is Also for Sale in Most of Them
Lilly does not expect to file for approval until the first quarter of 2027. Search the drug's name today and you can have a vial by the weekend. The gap between those two facts is where the harm happens.
Aug 20, 2026
